The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis

Cytokine

Volumn 76, Issue 2, 2015, Pages 280-287

  Abdel Galil, Sahar M ^a,b   Ezzeldin, Nillie ^a   El Boshy, Mohamed E ^b  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b UMM AL QURA UNIVERSITY   (Saudi Arabia)

Author keywords

Disease activity; IL 17; IL 6; Lupus nephritis; SLE

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 17; INTERLEUKIN 6;

ADULT; ANEMIA; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REMISSION; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; PATHOPHYSIOLOGY; VALIDATION STUDY;

BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; LUPUS NEPHRITIS; MALE; ROC CURVE;

EID: 84943819103     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.05.007     Document Type: Article

References (40)

1. Talaat R.M., Mohamed S.F., Bassyouni I.H., et al. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine 2015, 72:146-153.
2. Liang B., Debra B., Gardner D.B., et al. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006, 119:296-305.
3. Yap Y.H., Lai K.N. The role of cytokines in the pathogenesis of systemic lupus erythematosus - from bench to bedside. Nephrology 2013, 18:243-255.
4. Eilertsen G.O., Nossent J.C. APRIL levels strongly correlate with IL-17 in systemic lupus erythematosus. Lupus 2014, 1-9.
5. Rahman A., Senberg D.A. Systemic lupus erythematosus. New Engl J Med 2008, 358:929-939.
6. Martin J.C., Baeten D.L., Josien R. Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. Clin Immunol 2014, 154:1-12.
7. Kolls J.K., Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 20:467-476.
8. Nalbandian A., Crispín J.C., Tsokos G.C. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009, 157:209-215.
9. Ripley B.J.M., Goncalves B., Isenberg D.A., et al. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis 2005, 64:849-853.
10. Maier-Moore J.S., Horton C.G., Mathews S.A., et al. Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary sjogren's syndrome features in lupus-prone sle1. Yaa mice. Arthritis Rheumatol 2014, 66(9):2521-2531.
11. Jacob N., Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:228.
12. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
13. Gladman D.D., Ibanez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002, 29:288-291.
14. Singh J.A., Furst D.E., Bharat A., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012, 64:625-639.
15. Harrington L.E., Hatton R.D., Mangan P.R., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 15:1123-1132.
16. Wng CKo, Wan Lit L.C., Tamb L.S., et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008, 127:385-393.
17. Wang H.-X., Chu S., Li J., et al. Increased IL-17 and IL-21 producing TCRabCD4_CD8_T cells in Chinese systemic lupus erythematosus patients. Lupus 2014, 23:643-654.
18. Wong C.K., Ho C.Y., Li E.K., et al. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000, 9:589-593.
19. Pan H.F., Ye D.Q., Li X.P. Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat Clin Pract Rheumatol 2008, 4:352-353.
20. Crispin J.C., Tsokos G.C. IL-17 in systemic lupus erythematosus. J Biomed Biotechnol 2010, 943254.
21. Tsokos G.C. Systemic lupus erythematosus. New Engl J Med 2011, 365:2110-2121.
22. Hahn B.H., Mcmahon M.A., Wilkinson A., et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012, 64(6):797-808.
23. Zhao X.F., Pan H.F., Yuan H., et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2010, 37:81-85.
24. Vincent F.B., Northcott M., Hoi A., et al. Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther 2013, 15:R97.
25. Crispin J.C., Oukka M., Bayliss G., et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008, 181:8761-8766.
26. Jolly M., Francis S., Aggarwal R., et al. Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. Lupus 2014, 23(9):881-888.
27. Iwano M., Dohi K., Hirata E., et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin. Nephrol 1993, 40:16-21.
28. Tsai C.Y., Wu T.H., Yu C.L., et al. Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 2000, 85:207-214.
29. Herrera-Esparza R., Barbosa-Cisneros O., Villalobos-Hurtado R., et al. Renal expression of IL-6 and TNF α genes in lupus nephritis. Lupus 1998, 7:154-158.
30. Klashman D.J., Martin R.A., Martinez-Maza O., et al. In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells. Arthritis Rheum 1991, 34:276-286.
31. Linker-Israeli M., Deans R.J., Wallace D.J., et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991, 147:117-123.
32. Kitani A., Hara M., Hirose T., et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol 1992, 88:75-83.
33. Lam Q.L.K., KoK Hung., Zheng B.J., et al. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Nat Acad Sci USA 2008, 105(39):14993-14998.
34. Ogura H., Murakami M., Okuyama Y., Tsuruoka M., Kitabayashi C., Kanamoto M., et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008, 29:628-636.
35. Dong G., Ye R., Shi W., et al. IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Clin Med J (Engl) 2003, 116:543-548.
36. Sabry A., Elbasyouni S.R., Sheashaa H., et al. A correlation between levels of TNF-α and IL-6 and hematological involvement in SLE Egyptian patients with lupus nephritis. Int Urol Nephrol 2006, 38(3-4):731-737.
37. Ershler W.B. Biological interactions of aging and anemia: a focus on cytokines. J Am Geriatr Soc 2003, 51(suppl):S18-S21.
38. Jason J., Archibald L.K., Nwanyanwu O.C., et al. The effects of iron deficiency on lymphocyte cytokine production and activation: preservation of hepatic iron but not at all cost. Clin Exp Immunol 2001, 126:466-473.
39. Gigante A1, Gasperini M.L., Afeltra A., et al. Cytokines expression in SLE nephritis. Eur Rev Med Pharmacol Sci 2011, 15(1):15-24.
40. Sabry A., Sheashaa H., El-husseini A., et al. Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine 2006, 35:148-153.